Oral corticosteroids and fracture risk: relationship to daily and cumulative doses.

By T. V. Staa, H. Leufkens, L. Abenhaim, B. Zhang, Chris Cooper. Rheumatology, 2000

719 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Orthopedics and Sports Medicine

View Paper: https://www.semanticscholar.org/paper/368dcfb1d836475f1d6bfdfb65b8a51e407bff82

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. Jennifer N. Brudno
2. J. Kochenderfer

In Orthopedics and Sports Medicine

1. Chris Cooper
2. Eugene V. McCloskey
3. J. Kanis
4. Nicholas C. Harvey
5. H. Johansson
6. J. Reginster
7. R. Rizzoli
8. on behalf of the International Osteoporosis Foundation

Citations in the corpus

• UK clinical guideline for the prevention and treatment of osteoporosis (2017, background): “use of glucocorticoids is, however, not solely dependent upon bone loss and BMD-independent risks have been identified [36, 37] (Evidence level 1a).”
• The clinician’s guide to prevention and treatment of osteoporosis (2022, background): “Glucocorticoids cause a dose-dependent loss of BMD in the spine and hip, with the greatest loss in vertebral trabecular bone [274].”
• Pharmacokinetics and Pharmacodynamics of Systemically Administered Glucocorticoids (2005, background): “They inhibit dose compared with the cumulative dose.[221] Skin the differentiation and antigen presentation of atrophy is due to suppression of cutaneous cell prolimacrophages and dendritic cells[184,207] and thus supferation and protein synthesis (e.”